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Background and Aims: The pathogenesis of Non-Alcoholic Fatty Liver Disease (NAFLD) and steatohepatitis (NASH) is likely due to the interaction between a deranged metabolic milieu and local mediators of hepatic inflammation and fibrosis. We investigated a panel of serum non-invasive biomarkers of collagen remodelling and explored their association with metabolic derangements and liver damage to elucidate their complex interplay in a well-characterized
cohort of non-diabetic NAFLD patients.
Method: We enrolled 52 non-diabetic subjects with biopsy proven NAFLD who underwent a double tracers oral glucose tolerance test. Using tracers data we measured endogenous glucose production (EGP) and lipolysis by glycerol rate of appearance (GlycRa) and we calculated indexes of IR in the liver (Hep-IR = EGP × insulin) and in the adipose tissue (Lipo-IR = GlycRa × insulin and AT-IR = free fatty acids × insulin). Fasting c-peptide (CP) levels were measured using a
chemiluminescence assay. Fibrogenesis biomarkers PRO-C3 and PROC6 as well as macrophage activation biomarker sCD163, were measured by ELISA. Histology was scored according to Kleiner.
Results: Overall, fasting CP, PRO-C3, PRO-C6 levels directly correlated with BMI and waist circumference (all p < 0.03). Among IR indexes, PRO-C3 and PRO-C6 correlated with Hep-IR (rS = 0.32, p = 0.025; rS =0.38, p = 0.006), adipo-IR (both Lipo-IR [rS = 0.36, p = 0.010; rS = 0.37,
p = 0.007] and AT-IR [rS = 0.36, p = 0.010; rS = 0.37, p = 0.008]) as well as with basal insulin (rS = 0.3, p = 0.005 and rS = 0.34, p = 0.013) and CP levels (rS = 0.51, p < 0.001; rS = 0.55, p < 0.001). On the opposite, sCD163 levels did not correlate with insulin levels but increased proportionally with adipo-IR (both Lipo-IR [rS = 0.28, p = 0.05] and AT-IR [rS = 0.30, p = 0.032]). Concerning the ability to discriminate hepatic fibrosis, CP and PRO-C6 levels were able to distinguish F0/F1
from F2 (p = 0.013; p = 0.05, respectively) while PRO-C3 and sCD163 levels discriminated F2 from F3/F4 (p = 0.009; p = 0.002, respectively). By biomarkers combination, the best performance for the identification of F3/F4 was obtained with CP and sCD163 with an area under the receiver operating curve (AUROC) of 0.91 (PPV = 83%; NPV = 91%).
Conclusion: In non-diabetic patients with NAFLD, the combination between CP and sCD163 provides the best performance for the assessment of severe fibrosis (F3/F4) yielding both a high positive and negative predictive value.

